Wall Street analyst estimates for CRISPR Therapeutics AG (CRSP): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $40.4M | $15.1M – $100M | -$4.36 | 15 |
| 2027E | $139M | $2.0M – $498M | -$3.33 | 15 |
| 2028E | $518M | $29.3M – $3.5B | -$2.01 | 10 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 22 |
| Hold | 14 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 38 |
| Avg rating (−2 sell to +2 buy) | 0.53 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-1.04 | ||
| 2026-08-03 | $-0.94 | $-1.19 | +21.0% |
| 2026-05-04 | $-1.28 | $-1.19 | -7.6% |
| 2026-02-12 | $-1.37 | $-1.15 | -19.1% |
| 2025-11-10 | $-1.17 | $-1.26 | +7.1% |
| 2025-08-05 | $-2.40 | $-1.47 | -63.3% |
| 2025-05-06 | $-1.58 | $-1.27 | -24.4% |
| 2025-02-11 | $-0.44 | $-1.15 | +61.7% |
Valuation Ratios
| Price / Book | 2.84 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $719,000 | $913.1M | $436,000 | $370.0M | $35.0M | $3.5M |
| Cost of Revenue | $42.2M | $69.8M | $113.8M | $179.4M | $269.4M | $101.2M | $110.2M | $130.2M | $110.2M | $233.0M |
| Gross Profit | -$37.1M | -$28.8M | -$110.6M | $110.2M | -$268.7M | $811.9M | -$109.8M | $239.8M | -$75.2M | -$229.4M |
| Research & Development | $42.2M | $69.8M | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M |
| Selling, General & Admin | $31.1M | $35.8M | $48.3M | $63.5M | $85.7M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M |
| Operating Expenses | $73.3M | $105.6M | $162.1M | $63.5M | $85.7M | $438.4M | $563.3M | $462.3M | $391.3M | $338.9M |
| Operating Income | -$68.1M | -$64.6M | -$158.9M | $46.7M | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$568.3M |
| EBITDA | -$13.7M | -$61.6M | -$155.4M | $51.5M | -$345.3M | $397.5M | -$626.3M | -$130.9M | -$343.4M | -$558.5M |
| Interest Expense | $8.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-tax Income | -$22.7M | -$66.6M | -$164.4M | $67.3M | -$348.1M | $379.5M | -$650.5M | -$150.7M | -$362.7M | -$578.0M |
| Income Tax | $484,000 | $1.7M | $553,000 | $448,000 | $809,000 | $1.9M | -$325,000 | $2.9M | $3.6M | $3.6M |
| Net Income | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| EPS | -$1.89 | -$1.71 | -$3.44 | $1.23 | -$5.29 | $4.97 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| EPS (Diluted) | -$1.89 | -$1.71 | -$3.44 | $1.17 | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Shares Outstanding (Diluted) | 12.3 M | 40.1 M | 48.0 M | 56.9 M | 65.9 M | 80.4 M | 77.7 M | 79.2 M | 84.4 M | 89.9 M |
Price
| Price | $51.42 (closing price, October 30, 2026) |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | CH |
Related companies: BEAM · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks